The influence of perioperative transfusion (PT) on outcome following surgery for gastric cancer (GC) remains controversial, with randomized trials lacking and observational series confounded by patient risk factors. This analysis determines the association between reception of leukocyte-depleted blood products and post-operative survival for GC. Data from 610 patients who underwent curative surgery for GC in a German tertiary care clinic from 2001 to 2013 were included. Kaplan-Meier survival curves and Cox proportional hazards regression were applied to determine the association of PT and clinical and patient risk factors for overall and relapse-free survival. Propensity score analysis was performed to adjust for observational biases in reception of PT. Higher Union International Contre le Cancer/American Joint Committee on Cancer (UICC/AJCC)-stages (P<0.001), postoperative complications and severity according to the Clavien-Dindo (CD) classification (P<0.001), PT (P=0.02), higher age (P<0.001), and neoadjuvant chemotherapy (P<0.001) were related to increased mortality rates. Higher UICC-stages (P<0.001), neoadjuvant chemotherapy (P<0.001), and type of surgery (P=0.02) were independently associated with increased relapse rates. Patients were more likely to receive PT with higher age (P=0.05), surgical extension to adjacent organs/structures (P=0.002), tumor location (P= 0.003), and female gender (P=0.03). In the adjusted propensity score weighted analysis, PT remained associated with an increased risk of death (hazard ratio (HR): 1.31, 95% CI: 1.01-1.69, P=0.04). Because of the association of PT with negative influence on patient survival following resection for GC, risks from application of blood products should be weighed against the potential benefits.
- Gastric cancer
- Perioperative blood transfusion
ASJC Scopus subject areas